1. Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs;Wise, R.; Andrews, J.M.; Bedford, K.A.;Antimicrob Agents Chemother,1978
2. Adverse reactions to piperacillin in cystic fibrosis;Stead, R.I.; Kennedy, H.G.; Hodson, M.E.; Batten, J.C.;Lancet,1984
3. Piperacillin therapy for serious bacterial infections;Winston, D.J.; Murphy, W.; Young, L.S.; Hewitt, W.L.;Am J Med,1980
4. Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperaciflin in combination with tobramycin;Moller, N.E.; Eriksen, K.R.; Feddersen, D.;Eur J Respir Dis,1982
5. Alternative antibiotics against pseudomonas infections in cystic fibrosis. In vitro Stead, Kennedy, Hodson, Batten activity, pharmacokinetics, and double-blind randomized clinical trial with azlocillin, piperacillin, cefoperazone, ceftazidime, cefsulodin, cefotaxime and moxalactam. Preliminary results;Agostini, M.; Barlocco, G.; Bonomi, U.;Drugs in Experimental and Clinical Research,1983